| pubmed-article:16750629 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16750629 | lifeskim:mentions | umls-concept:C1120843 | lld:lifeskim |
| pubmed-article:16750629 | lifeskim:mentions | umls-concept:C0268563 | lld:lifeskim |
| pubmed-article:16750629 | lifeskim:mentions | umls-concept:C1366876 | lld:lifeskim |
| pubmed-article:16750629 | lifeskim:mentions | umls-concept:C1152564 | lld:lifeskim |
| pubmed-article:16750629 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:16750629 | pubmed:dateCreated | 2006-7-17 | lld:pubmed |
| pubmed-article:16750629 | pubmed:abstractText | p38 inhibitors based on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-one and 3,4-dihydropyrido[4,3-d]pyrimidin-2-one platforms were synthesized and preliminary SAR explored. Among the pyrimido-pyrimidones the emergence of two sub-types of analogs-C7-amino-pyrimidines such as 24 and C7-amino-piperidines such as 42-characterized with good p38 inhibition and better off-target profiles in terms of ion channel activities was significant. Representative compound 54 in the pyrido-pyrimidone class was found to be equipotent with corresponding analog in the quinazolinone series. | lld:pubmed |
| pubmed-article:16750629 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16750629 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16750629 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16750629 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16750629 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:16750629 | pubmed:author | pubmed-author:O'KeefeStephe... | lld:pubmed |
| pubmed-article:16750629 | pubmed:author | pubmed-author:O'NeillEdward... | lld:pubmed |
| pubmed-article:16750629 | pubmed:author | pubmed-author:ThompsonJames... | lld:pubmed |
| pubmed-article:16750629 | pubmed:author | pubmed-author:NatarajanSwam... | lld:pubmed |
| pubmed-article:16750629 | pubmed:author | pubmed-author:WisnoskiDavid... | lld:pubmed |
| pubmed-article:16750629 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16750629 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:16750629 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16750629 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16750629 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16750629 | pubmed:pagination | 4400-4 | lld:pubmed |
| pubmed-article:16750629 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:meshHeading | pubmed-meshheading:16750629... | lld:pubmed |
| pubmed-article:16750629 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16750629 | pubmed:articleTitle | p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones. | lld:pubmed |
| pubmed-article:16750629 | pubmed:affiliation | Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. ravi_natarjan@merck.com | lld:pubmed |
| pubmed-article:16750629 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:16750629 | lld:chembl |
